143 related articles for article (PubMed ID: 37713330)
1. Real time
Kim DW; Beato F; Kim Y; Tassielli AF; Dai R; Denbo JW; Hodul PJ; Malafa MP; Fleming JB
Oncotarget; 2023 Sep; 14():811-818. PubMed ID: 37713330
[TBL] [Abstract][Full Text] [Related]
2. Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.
Roife D; Dai B; Kang Y; Perez MVR; Pratt M; Li X; Fleming JB
Clin Cancer Res; 2016 Dec; 22(24):6021-6030. PubMed ID: 27259561
[TBL] [Abstract][Full Text] [Related]
3. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
4. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Nicolle R; Gayet O; Duconseil P; Vanbrugghe C; Roques J; Bigonnet M; Blum Y; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Puleo F; Augustin J; Emile JF; Svrcek M; Arsenijevic T; Hammel P; Giovannini M; Grandval P; Dahan L; Moutardier V; Gilabert M; Van Laethem JL; Bachet JB; Cros J; Iovanna J; Dusetti NJ
Ann Oncol; 2021 Feb; 32(2):250-260. PubMed ID: 33188873
[TBL] [Abstract][Full Text] [Related]
5. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
Hue JJ; Dorth J; Sugumar K; Hardacre JM; Ammori JB; Rothermel LD; Saltzman J; Mohamed A; Selfridge JE; Bajor D; Winter JM; Ocuin LM
Am Surg; 2021 Sep; 87(9):1386-1395. PubMed ID: 34382877
[TBL] [Abstract][Full Text] [Related]
8. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
Hattangadi JA; Hong TS; Yeap BY; Mamon HJ
Cancer; 2009 Aug; 115(16):3640-50. PubMed ID: 19514088
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Morak MJ; van der Gaast A; Incrocci L; van Dekken H; Hermans JJ; Jeekel J; Hop WC; Kazemier G; van Eijck CH
Ann Surg; 2008 Dec; 248(6):1031-41. PubMed ID: 19092348
[TBL] [Abstract][Full Text] [Related]
10. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.
Lim CY; Chang JH; Lee WS; Lee KM; Yoon YC; Kim J; Park IY
Pancreatology; 2018 Dec; 18(8):913-927. PubMed ID: 30292644
[TBL] [Abstract][Full Text] [Related]
11. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
12. Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue.
Díaz-Alejo JF; April-Monn S; Cihova M; Buocikova V; Villalón López J; Urbanova M; Lechuga CG; Tomas M; Dubovan P; Sánchez BL; Páez SC; Sanjuanbenito A; Lobo E; Romio de la Heras E; Guerra C; de la Pinta C; Barreto Melian E; Rodríguez Garrote M; Carrato A; Ruiz-Cañas L; Sainz B; Torres A; Smolkova B; Earl J
J Vis Exp; 2023 May; (195):. PubMed ID: 37306424
[TBL] [Abstract][Full Text] [Related]
13. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis.
Showalter TN; Rao AS; Rani Anne P; Rosato FE; Rosato EL; Andrel J; Hyslop T; Xu X; Berger AC
Ann Surg Oncol; 2009 Aug; 16(8):2116-22. PubMed ID: 19437078
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Hsu CC; Herman JM; Corsini MM; Winter JM; Callister MD; Haddock MG; Cameron JL; Pawlik TM; Schulick RD; Wolfgang CL; Laheru DA; Farnell MB; Swartz MJ; Gunderson LL; Miller RC
Ann Surg Oncol; 2010 Apr; 17(4):981-90. PubMed ID: 20087786
[TBL] [Abstract][Full Text] [Related]
15. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.
Fischer R; Breidert M; Keck T; Makowiec F; Lohrmann C; Harder J
Saudi J Gastroenterol; 2012; 18(2):118-21. PubMed ID: 22421717
[TBL] [Abstract][Full Text] [Related]
16. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Assessment of Chemosensitivity Test in Xeno-free Culture of Autologous
Malignant Effusion Cells from Patients with Advanced Lung Adenocarcinoma].
Chen L; Yang S; Jiang J; Zhang Y; Feng H; Cao J; Ge X; Xie W
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):584-9. PubMed ID: 27666547
[TBL] [Abstract][Full Text] [Related]
18. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy.
Demyan L; Habowski AN; Plenker D; King DA; Standring OJ; Tsang C; St Surin L; Rishi A; Crawford JM; Boyd J; Pasha SA; Patel H; Galluzzo Z; Metz C; Gregersen PK; Fox S; Valente C; Abadali S; Matadial-Ragoo S; DePeralta DK; Deutsch GB; Herman JM; Talamini MA; Tuveson DA; Weiss MJ
Ann Surg; 2022 Sep; 276(3):450-462. PubMed ID: 35972511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]